(Q37179377)

18 August 2017

1 reference

title

Bendamustine as a model for the activity of alkylating agents (English)

1 reference

18 August 2017

1 reference

Christos Apostolopoulos

1

1 reference

18 August 2017

Leandro Castellano

2

1 reference

18 August 2017

Justin Stebbing

3

1 reference

18 August 2017

Georgios Giamas

4

1 reference

18 August 2017

language of work or name

English

0 references

publication date

1 June 2008

1 reference

18 August 2017

1 reference

18 August 2017

volume

4

1 reference

18 August 2017

issue

3

1 reference

18 August 2017

page(s)

323-332

1 reference

Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.323

Pharmacogenomics--drug disposition, drug targets, and side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.323

Cancer pharmacogenomics: powerful tools in cancer chemotherapy and drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.323

Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.323

21 January 2018

Cancer pharmacogenetics

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.323

Pharmacogenomics, regulation and signaling pathways of phase I and II drug metabolizing enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.323

Induction of phase I, II and III drug metabolism/transport by xenobiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.323

Generating mutations but providing chemosensitivity: the role of O6-methylguanine DNA methyltransferase in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.323

Identifying DNA methylation biomarkers of cancer drug response

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.323

Reversal of resistance to oxazaphosphorines

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.323

Pharmacogenetics of cyclophosphamide in patients with hematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.323

Current pharmacogenomic approaches to clinical drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.323

Pharmacogenetics of Drug Metabolising Enzymes: Importance for Personalised Medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.323

Molecular targeting and pharmacogenomics in the management of advanced bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.323

Pharmacogenetics and stomach cancer: an update.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.323

Pharmacogenetics of alkylator-associated acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.323

The role of genetic variability in drug metabolism pathways in breast cancer prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.323

Sarcomas and pharmacogenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.323

Pharmacogenetic determinants of outcome in acute lymphoblastic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.323

Metabolism and mechanisms of action of bendamustine: rationales for combination therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.323

Cytotoxic efficacy of bendamustine in human leukemia and breast cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.323

In vitro studies with bendamustine: enhanced activity in combination with rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.323

In vitro evaluation of bendamustine induced apoptosis in B-chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.323

Reduced growth rate accompanied by aberrant epidermal growth factor signaling in drug resistant human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.323

Bendamustine as salvage treatment in patients with advanced progressive breast cancer: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.323

Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.323

High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.323

Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.323

Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.323

[Bendamustine, vincristine, prednisolone (BOP) in therapy of advanced low-grade non-Hodgkin lymphoma]].

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.323

Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.323

Efficacy and toxicity of bendamustine in patients with relapsed low-grade non-Hodgkin's lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.323

High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.323

Bendamustine/Mitoxantrone/Rituximab (BMR): a very effective, well tolerated outpatient chemoimmunotherapy for relapsed and refractory CD20-positive indolent malignancies. Final results of a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.323

Fludarabine and bendamustine in refractory and relapsed indolent lymphoma--a multicenter phase I/II Trial of the east german society of hematology and oncology (OSHO).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.323

Role of surgery in the treatment of bilio-pancreatic cancer: the European experience

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.323

Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and predniso

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.323

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.323

Phase I trial of radiochemotherapy with bendamustine in patients with recurrent squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.323

Phase II trial of second-line bendamustine chemotherapy in relapsed small cell lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.323

Phase I studies with bendamustine: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.323

A phase I study of bendamustine hydrochloride administered once every 3 weeks in patients with solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.323

Weekly administration of bendamustine: a phase I study in patients with advanced progressive solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.323

Salvage chemotherapy for metastatic breast cancer: results of a phase II study with bendamustine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.323

A pilot study of bendamustine in advanced bile duct cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.3.323

21 January 2018

Identifiers

DOI

10.2217/14796694.4.3.323

1 reference

18 August 2017

1 reference